Back to Search Start Over

O31 Integrative analysis reveals a molecular stratification of systemic autoimmune diseases

Authors :
Carlo Chizzolini
Yolanda Jiménez Gómez
Pier Luigi Meroni
M.C. Castro-Villegas
Ralf Lesche
Fernanda Genre
Javier Martín
Raquel Faria
Márta Bocskai
Tommaso Schioppo
Emanuele de Rinaldis
Divi Cornec
Torsten Witte
Pierre-Emmanuel Jouve
Sikander Hayat
Johan Frostegård
Guillermo Barturen
Christophe Jamin
Laleh Khodadadi
Alfonso Corrales Martínez
Quentin Simon
Mariana Brandão
Chris Chamberlain
Alain Saraux
Javier Rodríguez-Ubreva
Francesc Català-Moll
Michaela Lehner
Ricard Cervera
Tania F. Rowley
Tianlu Li
Attila Balog
Enrique de Ramón
Maria Angeles Aguirre-Zamorano
Elena Carnero-Montoro
Rafaela Ortega-Castro
László Kovács
Velia Gerl
Carolina Artusi
Nancy Azevedo
Martin Kerick
Antonio López-Berrio
Esmeralda Neves
Anne-Lise Maudoux
Bénédicte Rouvière
Bernard Lauwerys
Maria Gerosa
Yiannis Ioannou
Fátima Farinha
Ian White
Tania Anjos
Sepideh Babaei
N.T. Baerlecken
Katja Kniesch
Jonathan Cremer
Joerg Mueller
Julie Ducreux
Lucas Le Lann
Norberto Ortego
Jerome Wojcik
Marialbert Acosta-Herrera
Maria Hernandez-Fuentes
Héctor Navarro-Linares
Maria Orietta Borghi
Inmaculada Jiménez Moleón
António Marinho
Rocío Aguilar-Quesada
Enrique Raya
Falk Hiepe
Raquel López Mejías
Mcdonald Fiona Mcdougall
Robert J. Benschop
Georg Stummvoll
Isabel Díaz Quintero
Esteban Ballestar
Aleksandra Maria Dufour
Jordi Martorell-Marugán
Elena Trombetta
Manuel Rodriguez Maresca
Miguel A. González-Gay
Valérie Devauchelle-Pensec
Maria Juarez
Carlos Vasconcelos
Doreen Belz
Yves Renaudineau
Donatienne Wynar
Jacqueline Marovac
Aurélie De Groof
Sandrine Jousse-Joulin
Alejandro Escudero-Contreras
Laurence Laigle
Ignasi Rodríguez-Pintó
Zuzanna Makowska
Isabel Almeida
Lorenzo Beretta
Damiana Álvarez-Errico
Nieves Varela
Montserrat Alvarez
Concepción Marañón
Ricardo Blanco Alonso
Daniel Toro-Domínguez
Ana Campar
Manuel Martínez-Bueno
Barbara Vigone
Francisco Javier Garrancho
Rik Lories
Gabriella Kádár
Michael Zauner
Silvia Thiel
Pedro Carmona-Sáez
María Concepción Fernández Roldán
Magdolna Deák
Marta E. Alarcón-Riquelme
Rosario Lopez-Pedrera
Qingyu Cheng
Sonja Dulic
Sara Remuzgo
Ana Lisa Taylor Tavares
Gerard Espinosa
Gaia Montanelli
Nuria Barbarroja
Sambasiva P. Rao
Eduardo Collantes-Estevez
Anne Buttgereit
Begoña Ubilla Garcia
Ernst R. Dow
Jorge Kageyama
Antonio Garcia-Gomez
Jacques-Olivier Pers
Nicolas Hunzelmann
Ellen De Langhe
Source :
Oral presentations.
Publication Year :
2020
Publisher :
Lupus Foundation of America, 2020.

Abstract

Background Clinical heterogeneity, a hallmark of systemic autoimmune diseases (SADs) impedes early diagnosis and effective treatment, issues that may be addressed if patients could be grouped into a molecular defined stratification. Methods With the aim of reclassifying SADs independently of the clinical diagnoses, unsupervised clustering of integrated whole blood transcriptome and methylome cross-sectional data of 918 patients with 7 SADs and 263 healthy controls was undertaken. An inception cohort prospectively followed for 6 and 14 months was studied to validate the results in early cases and analyze if cluster assignment was modified with time. Results Four clusters were identified Three aberrant clusters were ‘acute phase inflammatory’, ‘T cell immunity’, and ‘interferon’, each including all diagnoses, were defined by genetic, clinical, serological and cellular features. A fourth cluster showed no specific molecular pattern, to which 74% of healthy controls clustered with patients. The inception cohort showed that most patients were either assigned always to the same cluster or moved from the healthy-like cluster to a single aberrant cluster resembling the relapsing-remitting dynamic of these diseases, showing that single aberrant molecular signatures characterize each individual patient. Conclusions Patients with SADs share molecular signatures and can be therefore stratified into three disease clusters differentiating each patient into a specific molecular disease pathway. Such assignment is stable with time. These results have important implications for understanding disease progression and therapy design marking a paradigm shift in our view of SADs. Acknowledgment This work has been supported through a grant from the Innovative Medicines Initiative Joint Undertaking No. 115565 and in-kind and in-cash contributions from the EFPIA partners. G.B. is supported by the Instituto de Salud Carlos III (ISCIII, Spanish Health Ministry), through the Sara Borrell subprogram (CD18/00153). The authors would like to particularly express their gratitude to the patients, nurses and many others who helped directly or indirectly in the consecution of this study.

Details

Database :
OpenAIRE
Journal :
Oral presentations
Accession number :
edsair.doi...........d7e4af04a47bfff7031b1c774b48c3ec